Catheter Precision (VTAK) Current Deferred Revenue (2017 - 2026)
Catheter Precision's (VTAK) quarterly Current Deferred Revenue came in at $126000.0 in Q1 2026, down 92.95% on a QoQ basis from $1.8 million in Q2 2021.
Catheter Precision (VTAK) Current Deferred Revenue (2017 - 2026) Analysis & Trends
Catheter Precision (VTAK) has 6 years of Current Deferred Revenue data on file, last reported at $126000.0 in Q1 2026.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $126000.0 in Q1 2026; TTM through Mar 2026 was $126000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $2.5 million, down 24.24% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $126000.0, down from $1.8 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for VTAK reached as high as $126000.0 in Q1 2026 and fell as low as $126000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Catheter Precision | 0.80 | -811,999.20 | 390,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 126,000.00 |
| Jun 30, 2021 | 1.79 Mn |
| Mar 31, 2021 | 1.78 Mn |
| Dec 31, 2020 | 2.50 Mn |
| Sep 30, 2020 | 1.73 Mn |
| Jun 30, 2020 | 1.86 Mn |
| Mar 31, 2020 | 1.96 Mn |
| Dec 31, 2019 | 3.30 Mn |
| Sep 30, 2019 | 1.92 Mn |
| Jun 30, 2019 | 2.04 Mn |
| Mar 31, 2019 | 1.95 Mn |
| Dec 31, 2018 | 1.72 Mn |
| Sep 30, 2018 | 1.75 Mn |
| Dec 31, 2017 | 1.71 Mn |